A Review on Advancement of Cancer Therapy with Metal Based Nanoparticle

  • Muhammad Irfan Government College University Faisalabad
  • Affifa Tajammal Department of Chemistry, Lahore Garrison University, Lahore P.O Box 54000, Pakistan
  • Ansa Gulnaz Department of Chemistry, Lahore Garrison University, Lahore P.O Box 54000, Pakistan
  • Mehtab Shareef Department of Chemistry, Lahore Garrison University, Lahore P.O Box 54000, Pakistan
DOI: https://doi.org/10.54692/lgujls.2024.0801329
Keywords: Nanoparticles, Nanomedicine, Noble Metal Nanoparticles, Cancerous Cell

Abstract

The primary cause of numerous diseases that frequently affect the human body is a compromised immune system. For instance, it can increase the body's susceptibility to infection, which also increases the body's resistance to medicines, by triggering pro-inflammatory reactions and even the loss of good cells and tissues. Metal nanoparticles have the potential to overcome the challenges caused by conventional chemotherapies. Metal nanoparticles play an essential role in the treatment of cancer by targeting, gene suppression, and drug delivery to the targeted area. The best suitable metal nanoparticles better work with targeted ligands to control the energy deposition within the tumors. Other than therapeutic advantages, metal nanoparticles are also helpful as a diagnostic tool for the imaging of cancerous cells. Moreover, metal nanoparticles provide beneficial options in controlled targeted drug delivery, instant diagnosis, and therapeutic methods. Nanoparticles are useful as therapies and diagnostics because cancer cells are heterogeneous. Breast cancer anti-cancer therapy is difficult due to the disease's aggressive spread to the body. Noble metal nanoparticles are used in the treatment of cancer because of their distinctive features, great biocompatibility, surface effects, and tiny size effects. Numerous cancer treatments have been developed thanks to advances in science and technology, but the global mortality rate for cancer patients is still astronomically high, necessitating conventional treatment approaches in order to preserve lives. Scientists are trying to find a cancer cure, working day and night. Due to their effectiveness and promising outcomes, nanoparticles for the treatment of cancer have acquired relevance.

REFERENCES

  1. Razak SA, Mohd Gazzali A, Fisol FA, Abdulbaqi I, Parumasivam T, Mohtar N, Wahab H (2021). Advances in nanocarriers for effective delivery of docetaxel in the treatment of lung cancer: An overview. Can. 13(3): 400.
  2. Becher B, Spath S, Goverman J (2017). Cytokine networks in neuroinflammation. Nat. Rev. Immunol. 17(1): 49-59.
  3. Chapekar MS (2000). Tissue engineering: challenges and opportunities. J. Biomed. Mat. Res. 53(6): 617-620.
  4. D’Acunto M, Cioni P, Gabellieri E, Presciuttini G (2021). Exploiting gold nanoparticles for diagnosis and cancer treatments. Nanotechnol. 32(19): 192001.
  5. Dhatchinamoorthy K, Colbert JD, Rock KL (2021). Cancer immune evasion through loss of MHC class I antigen presentation. Front. Immunol. 12: 636568.
  6. Diaz-Gil D, Fintelmann FJ, Molaei S, Elmi A, Hedgire SS, Harisinghani MG (2016). Prediction of 5-year survival in advanced-stage ovarian cancer patients based on computed tomography peritoneal carcinomatosis index. Abd. Radiol. 41(11): 2196-2202.
  7. Ding Y, Zhou YY, Chen H, Geng DD, Wu DY, Hong J, Zhang C (2013). The performance of thiol-terminated PEG-paclitaxel-conjugated gold nanoparticles. Biomat. 34(38): 10217-10227.
  8. Eniu A, Carlson RW, El Saghir NS, Bines J, Bese NS, Vorobiof D, Panel BHGIT (2008). Guideline implementation for breast healthcare in low‐and middle‐Income countries: Treatment resource allocation. Can. 113(S8): 2269-2281.
  9. Ferrari M (2005). Cancer nanotechnology: opportunities and challenges. Nat. Rev. Can. 5(3): 161-171.
  10. Ferraz da Costa DC, Casanova FA, Quarti J, Malheiros MS, Sanches D, Dos Santos PS, Silva JL (2012). Transient transfection of a wild-type p53 gene triggers resveratrol-induced apoptosis in cancer cells. PloS one. 7(11): e48746.
  11. Fortuin A, De Rooij M, Zamecnik P, Haberkorn U, Barentsz J (2013). Molecular and functional imaging for detection of lymph node metastases in prostate cancer. Int. J. Mol. Sci. 14(7): 13842-13857.
  12. Gupta SC, Sung B, Prasad S, Webb LJ, Aggarwal BB (2013). Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol. Sci. 34(9): 508-517.
  13. Gupta SK, Padmanabhan BR, Diene SM, Lopez-Rojas R, Kempf M, Landraud L, Rolain JM (2014). ARG-ANNOT, a new bioinformatic tool to discover antibiotic resistance genes in bacterial genomes. Antimicr. Agents Chemoth. 58(1): 212-220.
  14. Hainfeld JF, Slatkin DN, Smilowitz HM (2004). The use of gold nanoparticles to enhance radiotherapy in mice. Phy. Med. Biol. 49(18): N309.
  15. Hanahan D, Weinberg RA (2011). Hallmarks of cancer: the next generation. cell. 144(5): 646-674.
  16. Harrison BS, Atala A (2007). Carbon nanotube applications for tissue engineering. Biomat. 28(2): 344-353.
  17. Haynes SE, Hollopeter G, Yang G, Kurpius D, Dailey ME, Gan WB, Julius D (2006). The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat. Neurosci. 9(12): 1512-1519.
  18. Heidel JD, Davis ME (2011). Clinical developments in nanotechnology for cancer therapy. Pharmaceut. Res. 28(2): 187-199.
  19. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Gu X (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lanc. 395(10223): 497-506.
  20. Johnson M, Wesely E, Hussain MZ, Selvan N (2010). In vivo and in vitro phytochemical and antibacterial efficacy of Baliospermum montanum (Wïlld.) Muell. Arg. Asian Pacif. J. Trop. Med. 3(11): 894-897.
  21. Libutti SK, Paciotti GF, Byrnes AA, Alexander HR, Gannon WE, Walker M, Tamarkin L (2010). Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF NanomedicinePEGylated Colloidal Gold-rhTNF Nanomedicine Phase I Trial. Clin. Can. Res. 16(24): 6139-6149.
  22. Lovrić J, Cho SJ, Winnik FM, Maysinger D (2005). Unmodified cadmium telluride quantum dots induce reactive oxygen species formation leading to multiple organelle damage and cell death. Chem. Biol. 12(11): 1227-1234.
  23. Maggiorella L, Barouch G, Devaux C, Pottier A, Deutsch E, Bourhis J, Levy L (2012). Nanoscale radiotherapy with hafnium oxide nanoparticles. Fut. Oncol. 8(9): 1167-1181.
  24. Mavaddat N, Pharoah PD, Michailidou K, Tyrer J, Brook MN, Bolla MK, Shah M (2015). Prediction of breast cancer risk based on profiling with common genetic variants. JNCI: J. Nat. Can. Inst. 107(5).
  25. Meyer A, Coroiu A, Korner A (2015). One‐to‐one peer support in cancer care: a review of scholarship published between 2007 and 2014. Europ. J. Can. Care. 24(3): 299-312.
  26. Powell AC, Paciotti GF, Libutti SK (2010). Colloidal gold: a novel nanoparticle for targeted cancer therapeutics. Can. Nanotechnol. 375-384.
  27. Ratan ZA, Haidere MF, Nurunnabi M, Shahriar SM, Ahammad A, Shim YY, Cho JY (2020). Green chemistry synthesis of silver nanoparticles and their potential anticancer effects. Can. 12(4): 855.
  28. Siegel R, Ward E, Brawley O, Jemal A (2011). Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. Can. J. Clinic. 61(4): 212-236.
  29. Sinha R, Kim GJ, Nie S, Shin DM (2006). Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Can. Therapeu. 5(8): 1909-1917.
  30. Sperling RA, Gil PR, Zhang F, Zanella M, Parak WJ (2008). Biological applications of gold nanoparticles. Chem. Soc. Rev. 37(9): 1896-1908.
  31. Subhan MA, Muzibur Rahman M (2022). Recent Development in Metallic Nanoparticles for Breast Cancer Therapy and Diagnosis. Chem. Rec. e202100331.
  32. Tasic B, Yao Z, Graybuck LT, Smith KA, Nguyen TN, Bertagnolli D, Viswanathan S (2018). Shared and distinct transcriptomic cell types across neocortical areas. Nat. 563(7729): 72-78.
  33. Thornburg JM, Nelson KK, Clem BF, Lane AN, Arumugam S, Simmons A, Chesney J (2008). Targeting aspartate aminotransferase in breast cancer. Breast Can. Res. 10(5): 1-12.
  34. Vogelstein B, Kinzler KW (2004). Cancer genes and the pathways they control. Nat. Med. 10(8): 789-799.
  35. Wang F, Deng R, Wang J, Wang Q, Han Y, Zhu H, Liu X (2011). Tuning upconversion through energy migration in core–shell nanoparticles. Nat. Mat. 10(12): 968-973.
  36. Wang P, Zhang J, Zhang L, Zhu Z, Fan J, Chen L, Liu L (2013). MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells. Gastroenterol. 145(5): 1133-1143. e1112.
  37. Wicki A, Witzigmann D, Balasubramanian V, Huwyler J (2015). Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J. Contr. Rel. 200: 138-157.
  38. Xie Z, Paras CB, Weng H, Punnakitikashem P, Su LC, Vu K, Tang L, Yang J, Nguyen KT (2013). Dual growth factor releasing multi-functional nanofibers for wound healing. Acta biomat. 9(12): 9351-9359.
  39. Zhao R, Xiang J, Wang B, Chen L, Tan S (2022). Recent advances in the development of noble metal NPs for cancer therapy. Bioinorg. Chem. Appl.

 

 

 

Published
2024-03-15
Issue
Vol. 8 No. 1 (2024): LGU Journal of Life Sciences
Section
Articles